Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

To the Editor: In the Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58 (DECLARE–TIMI 58) trial, Wiviott et al. (Jan. 24 issue) 1 found that dapagliflozin did not result in a lower incidence of the composite of major adverse cardiovascular events (MACE) — defined as cardiovascular death, myocardial infarction, or ischemic stroke — than placebo (hazard ratio, 0.93; 95% confidence interval [CI], 0.84 to 1.03). There was no between-group difference in the incidence of cardiovascular death (hazard ratio, 0.98; 95% CI, 0.82 to 1.17), and the incidence of death from any cause was not lower in the dapagliflozin group than . . .